Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Income from Continuing Operations (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Income from Continuing Operations for 9 consecutive years, with 16964000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 31.92% year-over-year to 16964000.0, compared with a TTM value of 35231000.0 through Dec 2025, up 50.01%, and an annual FY2024 reading of 24100000.0, up 2325.3% over the prior year.
  • Income from Continuing Operations was 16964000.0 for Q4 2025 at Puma Biotechnology, up from 9128000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 19970000.0 in Q3 2024 and bottomed at 44672000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 2071000.0, with a median of 3548500.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations skyrocketed 1531.11% in 2023, then plummeted 443.68% in 2024.
  • Year by year, Income from Continuing Operations stood at 4123000.0 in 2021, then skyrocketed by 75.99% to 7256000.0 in 2022, then tumbled by 243.41% to 10406000.0 in 2023, then surged by 223.57% to 12859000.0 in 2024, then skyrocketed by 31.92% to 16964000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for PBYI at 16964000.0 in Q4 2025, 9128000.0 in Q3 2025, and 6165000.0 in Q2 2025.